A Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer

Trial Profile

A Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Neratinib (Primary) ; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NEFERTT
  • Sponsors Puma Biotechnology; Wyeth Pharmaceuticals
  • Most Recent Events

    • 09 Dec 2017 Results (n=966) of pooled subgroup analysis of NCT00445458, NCT00706030, NCT00398567, NCT00915018, NCT00741260 and NCT00300781trials assessing safety and efficacy of neratinib therapy in Asian patients from China, Hong Kong, Japan, Korea, Malaysia, Singapore, and Taiwan presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 06 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 14 Apr 2016 Puma Biotechnology media release, results from this trial published in JAMA Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top